Chimeric Therapeutics (ASX:CHM) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Days Payable?

Chimeric Therapeutics's average Accounts Payable for the six months ended in Dec. 2023 was A$7.06 Mil. Chimeric Therapeutics's Cost of Goods Sold for the six months ended in Dec. 2023 was A$0.00 Mil.

The historical rank and industry rank for Chimeric Therapeutics's Days Payable or its related term are showing as below:

ASX:CHM's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.145
* Ranked among companies with meaningful Days Payable only.

Chimeric Therapeutics's Days Payable stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Chimeric Therapeutics Days Payable Historical Data

The historical data trend for Chimeric Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Days Payable Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Days Payable

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Payable	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Chimeric Therapeutics's Days Payable

For the Biotechnology subindustry, Chimeric Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimeric Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's Days Payable falls into.

Chimeric Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Chimeric Therapeutics's Days Payable for the fiscal year that ended in Jun. 2023 is calculated as

	Days Payable (A: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jun. 2022 )	+	Accounts Payable (A: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (A: Jun. 2023 )	*	Days in Period
=	( (4.704	+	7.407)	/	2 )	/	0	*	365
=	6.0555					/	0	*	365
=	N/A

Chimeric Therapeutics's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (7.407	+	6.719)	/	2 )	/	0	*	365 / 2
=	7.063					/	0	*	365 / 2
=	N/A

Chimeric Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics (ASX:CHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

CHMMF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines